$PBSV

Pharma-Bio Serv, Inc.

CIK:0001304161|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2026	Jul. 31, 2025	Jul. 31, 2026	Jul. 31, 2025
Condensed Consolidated Statements of Operations (Unaudited)
REVENUES	$ 2,336,055	$ 1,963,083	$ 7,333,964	$ 6,851,460
COST OF SERVICES	1,644,321	1,388,821	5,017,815	4,690,363
GROSS PROFIT	691,734	574,262	2,316,149	2,161,097
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	763,546	888,139	2,337,820	2,665,487
LOSS FROM OPERATIONS	(71,812)	(313,877)	(21,671)	(504,390)
OTHER INCOME, NET	60,714	104,848	286,416	405,876
INCOME (LOSS) BEFORE INCOME TAX	(11,098)	(209,029)	264,745	(98,514)
INCOME TAX EXPENSE (CREDIT)	3,121	(4,779)	13,118	1,847
NET INCOME (LOSS)	$ (14,219)	$ (204,250)	$ 251,627	$ (100,361)
BASIC AND DILUTED EARNINGS (LOSS) PER COMMON SHARE	$ (0.001)	$ (0.009)	$ 0.011	$ (0.004)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	22,901,692	22,927,283	22,904,543	22,947,743
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	22,910,637	22,937,921	22,912,581	22,955,581

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2026	Jul. 31, 2025	Jul. 31, 2026	Jul. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS	$ (14,219)	$ (204,250)	$ 251,627	$ (100,361)
Adjustments to reconcile net income (loss) to net cash and cash equivalents provided by (used in) operating activities:
Gain on disposition of vehicle	0	0	(7,000)	0
Stock-based compensation	8,620	9,999	25,858	30,680
Depreciation and amortization	13,685	15,744	42,121	44,049
Amortization of operating lease right-of-use	0	42,512	29,388	125,850
Reinvested interests	(53,090)	(84,909)	(135,892)	(185,746)
Decrease (increase) in accounts receivable	295,791	675,376	(59,302)	551,482
Increase in other assets	(142,092)	(96,317)	(98,984)	(27,903)
Decrease in liabilities	(47,803)	(121,631)	(742,374)	(932,603)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	60,892	236,524	(694,558)	(494,552)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(1,390)	(2,036)	(6,122)	(6,294)
Proceeds from sale of vehicle	0	0	7,000	0
Marketable securities settlement (investment), net	(324,913)	1,630,816	552,432	(603,432)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(326,303)	1,628,780	553,310	(609,726)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase of common stock	0	(5,004)	(2,390)	(22,241)
Cash dividends paid to shareholders	0	0	(1,717,627)	(1,719,918)
NET CASH USED IN FINANCING ACTIVITIES	0	(5,004)	(1,720,017)	(1,742,159)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(7,749)	4,377	367	36,833
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(273,160)	1,864,677	(1,860,898)	(2,809,604)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	1,791,474	2,093,075	3,379,212	6,767,356
CASH AND CASH EQUIVALENTS - END OF PERIOD	1,518,314	3,957,752	1,518,314	3,957,752
SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION:
Income taxes	0	0	661,728	528,746
Interest	0	0	0	0
SUPPLEMENTARY SCHEDULES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Income tax withheld by clients to be used as a credit in the Company's income tax return	0	0	14,538	0
Decommissioned fully depreciated and/or amortized old property and equipment written off during the three months ended January 31, 2026	$ 0	$ 0	$ 69,043	$ 0

Condensed Consolidated Balance Sheets - USD ($)	Jul. 31, 2026	Oct. 31, 2025
Current assets
Cash and cash equivalents	$ 1,518,314	$ 3,379,212
Marketable securities	7,058,837	7,475,377
Accounts receivable	2,421,459	2,360,682
Prepaids and other assets	240,225	171,574
Total current assets	11,238,835	13,386,845
Property and equipment, net	80,060	116,059
Operating lease right-of-use	0	29,388
Other assets	120,753	120,754
Total assets	11,439,648	13,653,046
Current liabilities
Current operating lease liabilities	0	28,834
Accounts payable and accrued expenses	929,586	991,169
Current portion of US Tax Reform Transition Tax and income taxes payable	65,154	718,796
Total current liabilities	994,740	1,738,799
Total liabilities	994,740	1,738,799
Stockholders' equity
Preferred Stock, $0.0001 par value; authorized 10,000,000 shares; none outstanding	0	0
Common Stock, $0.0001 par value; authorized 50,000,000 shares; 23,519,672 and 23,519,672 shares issued, and 22,901,692 and 22,905,992 shares outstanding at July 31, 2026 and October 31, 2025, respectively	2,352	2,352
Additional paid-in capital	1,705,405	1,679,547
Retained earnings	9,067,589	10,533,589
Accumulated other comprehensive income	251,238	278,045
Stockholders' Equity before Treasury Stock	11,026,584	12,493,533
Treasury stock, at cost; 617,980 and 613,680 common shares held at July 31, 2026 and October 31, 2025, respectively	(581,676)	(579,286)
Total stockholders' equity	10,444,908	11,914,247
Total liabilities and stockholders' equity	$ 11,439,648	$ 13,653,046